The effect of phototherapy and oral Simvastatin in treatment of vitiligo
Phase 2
- Conditions
- Vitiligo.Vitiligo
- Registration Number
- IRCT20150825023753N11
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
The patients with vitiligo
Age above 14 years old
Exclusion Criteria
Patients with systemic diseases
Patients who use other therapeutic methods except light therapy
Patients with any liver disease
Patients with any kidney disease
Pregnant and lactating women
History of allergy to phototherapy
Taking medication that has interactions with simvastatin
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The amount of melanin pigment in the skin. Timepoint: Assessment the amount of melanin pigment at the start of the study and at the end of the first, second, third and fourths month after beginning the treatment. Method of measurement: Vitiligo Area Scoring Index (VASI Score).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Simvastatin's potential role in vitiligo repigmentation when combined with phototherapy?
How does the combination of phototherapy and Simvastatin compare to monotherapy in vitiligo treatment outcomes?
Are there specific biomarkers that predict response to combined phototherapy and Simvastatin in vitiligo patients?
What are the potential adverse events associated with Simvastatin and phototherapy in vitiligo treatment?
What other HMG-CoA reductase inhibitors or phototherapy regimens are being explored for vitiligo treatment efficacy?